NETJETS
21.5.2024 15:11:26 CEST | Business Wire | Press release
For the 23rd consecutive year, NetJets, the global leader in private aviation, proudly announces its partnership with Art Basel. To highlight its commitment to the arts, NetJets will collaborate with French abstract artist Silvère Jarrosson to create a new art collection exclusively for NetJets that will be displayed at the Art Basel shows in Basel, Paris and Miami Beach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521442854/en/
Silvère Jarrosson, credit Julien Benhamou
Born and raised in Paris, Jarrosson trained as a ballet dancer at the renowned Opera National de Paris at only 10 years old but transitioned into abstract painting a decade ago. His background in ballet is seen throughout his motion and fluidity while creating his works of art. Represented by contemporary art agency Studio Artera in Paris, Jarrosson is known for using his whole body to make his art – as he moves or ‘dances’ with the canvas to create his signature acrylic pieces.
At only 31 years of age, Jarrosson has received widespread praise and has had his work showcased globally. His art is featured in prestigious institutions such as the Villa Medici in Rome, the Unterlinden Museum in Colmar, the Lambert Collection in Avignon, the Crédit du Nord Collection, the Mobilier National and the Opera National de Paris, among others.
Jarrosson’s project created for NetJets, entitled “Inner Horizons”, offers Owners – the individuals and businesses who are clients of NetJets’ private jet ownership model – captivating insight into his world of poetic immersion, where his spectators become part of the creative inspiration for his shows and projects. His work will be featured in NetJets' exclusive area within the Collectors Lounge. Accessible only by Owners, it will offer a secluded space for guests to enjoy hospitality throughout the show week of Art Basel in Basel. The show aims to merge external travel experiences made possible by NetJets with inner travel experiences created by Jarrosson’s art.
Patrick Gallagher, President of Sales, Marketing & Service, commented: “We are delighted with this partnership. We admire the synergy from the movement Silvère uses to create his art pieces. His beautiful artwork truly moves observers who watch him paint. Despite coming from different industries, we align in our passion to both create and capture exceptional experiences for others. As many of our Owners are deeply interested in fine art, we believe this partnership will be both inspiring and exciting as Silvère’s career continues to flourish.”
Globally recognised for its revolutionary shared ownership business model, NetJets’ impeccable reputation spans more than 60 years and has reshaped how people fly private. NetJets proudly maintains and operates over 1,000 aircraft, grants access to more than 5,000 airports and employs over 8,300 private aviation professionals to deliver outstanding service.
About NetJets
Originally incorporated in 1964 as Executive Jet Airways, NetJets has been setting – and exceeding – industry standards for over 60 years. Today, NetJets is proud to be a Berkshire Hathaway company known for its unwavering commitment to safety and service. NetJets’ portfolio of distinctive companies, encompassing NetJets, Executive Jet Management, QS Partners and QS Security, offers a variety of customisable travel solutions, including shared ownership, lease and jet card options, aircraft management, private jet chartering, brokerage and acquisition services and specialised security services. This comprehensive suite of solutions is why so many of the world’s most discerning travellers choose NetJets generation after generation. It is also because NetJets has the largest, most diverse private jet fleet in the world, which grants anytime access to even the most remote destinations across the globe. To learn more about the leader in private aviation, visit netjets.com today.
About Studio Artera
Studio Artera is an art and talent agency based in Paris that supports the finest visual artists.
We represent artists and integrate art in all contexts by creating meaningful artistic collaborations with brands, companies, cultural institutions, and cities. Driven by the desire to reach an ever-wider audience through art, we build artistic narratives with our clients to inspire millions of people around the world.
Clients of Studio Artera include Louis Vuitton, Prada, Levi’s, Bombay Sapphire, the Hoxton Group, the City of Paris, Château Charmail, and Viva Technology.
To learn more about us, please visit www.studioartera.com
About Art Basel
Founded in 1970 by gallerists from Basel, Art Basel today stages the world’s premier art shows for Modern and contemporary art, sited in Basel, Miami Beach, Hong Kong, and Paris. Defined by its host city and region, each show is unique, which is reflected in its participating galleries, artworks presented, and the content of parallel programming produced in collaboration with local institutions for each edition. Art Basel’s engagement has expanded beyond art fairs through new digital platforms and initiatives such as the Art Basel and UBS Global Art Market Report. Art Basel’s Global Media Partner is The Financial Times. For further information, please visit artbasel.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521442854/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom